Molecular Minimal Residual Disease Monitoring in Acute Myeloid Leukemia
Autor: | Adrian G. Selim, Andrew S. Moore |
---|---|
Rok vydání: | 2018 |
Předmět: |
0301 basic medicine
Oncology Acute promyelocytic leukemia medicine.medical_specialty Myeloid Genetic heterogeneity business.industry Myeloid leukemia medicine.disease Minimal residual disease Pathology and Forensic Medicine body regions Fusion gene 03 medical and health sciences Leukemia 030104 developmental biology 0302 clinical medicine medicine.anatomical_structure hemic and lymphatic diseases 030220 oncology & carcinogenesis Internal medicine medicine Molecular Medicine business Childhood Acute Lymphoblastic Leukemia |
Zdroj: | The Journal of Molecular Diagnostics. 20:389-397 |
ISSN: | 1525-1578 |
Popis: | The ability to sensitively monitor minimal residual disease (MRD) has played a key role in improving the management and outcomes for a number of leukemias, particularly acute promyelocytic leukemia and childhood acute lymphoblastic leukemia. By contrast, MRD monitoring in acute myeloid leukemia (AML) has been limited by variable assay methodologies and a relative paucity of patient-specific MRD markers. Inter- and intratumor genetic heterogeneity poses significant challenges for the identification of molecular markers suitable for MRD monitoring in AML, particularly for those cases without structural chromosomal rearrangements associated with fusion genes. Furthermore, the need to discriminate which mutations may be suitable for MRD monitoring creates additional complexity. The mainstay of current molecular MRD monitoring is real-time quantitative PCR, targeting fusion genes, mutations, and gene overexpression. New technologies, particularly next-generation sequencing approaches, offer new ways to overcome these limitations. Here, the authors review the techniques available for molecular MRD monitoring in AML and discuss their utility in clinical practice. |
Databáze: | OpenAIRE |
Externí odkaz: |